Linzagolix

CHEMBL3668014 Phase 4 Approved Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
508.4 g/mol
LogP
3.4
Phase
4

This oral medication works by blocking GnRH receptors in the pituitary gland, reducing the production of sex hormones that fuel endometriosis and uterine fibroids, thereby reducing pain and bleeding. Unlike injected GnRH treatments, it is taken as a daily pill.

Molecular Weight

508.4000 g/mol

LogP

3.40

TPSA

143.00 Ų

Lipinski RO5

Fail

Therapeutic Areas

Mechanism of Action

Modulates gonadotropin-releasing hormone (GnRH) signaling, ultimately suppressing luteinizing hormone and follicle-stimulating hormone secretion and reducing gonadal steroid hormone production.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanism

Modulates gonadotropin-releasing hormone (GnRH) signaling, ultimately suppressing luteinizing hormone and follicle-stimulating hormone secretion and reducing gonadal steroid hormone production.

2D Structure

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

COc1cc(F)c(-n2c(=O)[nH]c3csc(C(=O)O)c3c2=O)cc1OCc1c(OC)ccc(F)c1F

InChI

InChI=1S/C22H15F3N2O7S/c1-32-14-4-3-10(23)18(25)9(14)7-34-16-6-13(11(24)5-15(16)33-2)27-20(28)17-12(26-22(27)31)8-35-19(17)21(29)30/h3-6,8H,7H2,1-2H3,(H,26,31)(H,29,30)

Molecular Formula

C22H15F3N2O7S

HBD / HBA

2 / 11

Rotatable Bonds

7

Heavy Atoms

35

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Frequently Asked Questions

This oral medication works by blocking GnRH receptors in the pituitary gland, reducing the production of sex hormones that fuel endometriosis and uterine fibroids, thereby reducing pain and bleeding. Unlike injected GnRH treatments, it is taken as a daily pill.

Modulates gonadotropin-releasing hormone (GnRH) signaling, ultimately suppressing luteinizing hormone and follicle-stimulating hormone secretion and reducing gonadal steroid hormone production.

Yes, Linzagolix is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3668014. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 16656889. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Medical Disclaimer

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.